Exploratory analysis of early toxicity of sunitinib in advanced hepatocellular carcinoma patients: Kinetics and potential biomarker value

Clinical Cancer Research

Volumn 17, Issue 4, 2011, Pages 918-927

  Zhu, Andrew X ^a   Duda, Dan G ^a   Ancukiewicz, Marek ^a   Di Tomaso, Emmanuelle ^a   Clark, Jeffrey W ^a   Miksad, Rebecca ^b   Fuchs, Charles S ^b   Ryan, David P ^a   Jain, Rakesh K ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BASIC FIBROBLAST GROWTH FACTOR; HEMOGLOBIN; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; PLATELET DERIVED GROWTH FACTOR; STEM CELL FACTOR; STROMAL CELL DERIVED FACTOR 1ALPHA; SUNITINIB; TUMOR MARKER; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN C; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN RECEPTOR 3;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BONE MARROW CELL; CANCER GROWTH; CANCER STAGING; CANCER SURVIVAL; CELL STIMULATION; CLINICAL EVALUATION; DIARRHEA; DOSE RESPONSE; DRUG DOSE REDUCTION; ERYTHROPOIESIS; EXPLORATORY RESEARCH; FATIGUE; FEMALE; HEMATOPOIESIS; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERTENSION; LIVER CELL CARCINOMA; LYMPHOCYTE COUNT; MALE; MONOCYTE; NAUSEA AND VOMITING; NEUTROPHIL COUNT; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RASH; SKIN TOXICITY; THROMBOCYTE COUNT; TREATMENT DURATION; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BIOLOGICAL MARKERS; BLOOD PLATELETS; CARCINOMA, HEPATOCELLULAR; CELL COUNT; CYTOKINES; FEMALE; HEMATOPOIETIC STEM CELLS; HEMOGLOBINS; HUMANS; INDOLES; LEUKOCYTES; LIVER NEOPLASMS; MALE; MIDDLE AGED; PYRROLES; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; TREATMENT OUTCOME;

EID: 79951818748     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-10-0515     Document Type: Article

References (35)

1. Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009;10:25-34.
2. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Raoul J, Zeuzem S, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359:378-90.
3. Chow LQ, Eckhardt SG. Sunitinib: from rational design to clinical efficacy. J Clin Oncol 2007;25:884-96. (Pubitemid 350002890)
4. Faivre S, Raymond E, Boucher E, Douillard J, Lim HY, Kim JS, et al. Safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma: an open-label, multicentre, phase II study. Lancet Oncol 2009;10:794-800.
5. Zhu AX, Duda DG, Sahani DV, Jain RK. Development of sunitinib in hepatocellular carcinoma: rationale, early clinical experience and correlative studies. Cancer J 2009;15:263-8.
6. Zhu AX, Sahani DV, Duda DG, di Tomaso E, Ancukiewicz M, Catalano OA, et al. Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study. J Clin Oncol 2009;27:3027-35.
7. Siegel AB, Cohen EI, Ocean A, Lehrer D, Goldenberg A, Knox JJ, et al. Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma. J Clin Oncol 2008;26:2992-8.
8. Thomas MB, Morris JS, Chadha R, Iwasaki M, Kaur H, Lin E, et al. Phase II trial of the combination of bevacizumab and erlotinib in patients who have advanced hepatocellular carcinoma. J Clin Oncol 2009;27:843-50.
9. Toh H, Chen P, Carr B, Knox JJ, Gill S, Steinberg J, et al. A phase II study of ABT-869 in hepatocellular carcinoma: interim analysis. J Clin Oncol 2009;27S suppl: abstr 4581.
10. Zhu AX, Blaszkowsky LS, Ryan DP, Clark JW, Muzikansky A, Horgan K, et al. Phase II study of gemcitabine and oxaliplatin in combination with bevacizumab in patients with advanced hepatocellular carcinoma. J Clin Oncol 2006;24:1898-903. (Pubitemid 46638989)
11. Bianchini D, Jayanth A, Chua YJ, Cunningham D. Epidermal growth factor receptor inhibitor-related skin toxicity: mechanisms, treatment, and its potential role as a predictive marker. Clin Colorectal Cancer 2008;7:33-43. (Pubitemid 351252449)
12. Schneider BP, Wang M, Radovich M, Sledge GW, Badve S, Thor A, et al. Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100. J Clin Oncol 2008;26:4672-8.
13. Vincenzi B, Santini D, Russo A, Addeo R, Giuliani F, Montella L, et al. Early skin toxicity as a predictive factor for tumor control in hepatocellular carcinoma patients treated with sorafenib. Oncologist 2010;15:85-92.
14. Alexandre I, Billemont B, Meric JB, Richard S, Rixe O. Axitinib induces paradoxical erythropoietin synthesis in metastatic renal cell carcinoma. J Clin Oncol 2009;27:472-3; author reply 473-4.
15. Alexandrescu DT, McClure R, Farzanmehr H, Dasanu CA. Secondary erythrocytosis produced by the tyrosine kinase inhibitors sunitinib and sorafenib. J Clin Oncol 2008;26:4047-8.
16. Fischer C, Carmeliet P, Conway EM. VEGF inhibitors make blood. Nat Med 2006;12:732-4. (Pubitemid 44050049)
17. Tam BY, Wei K, Rudge JS, Hoffman J, Holash J, Park SK, et al. VEGF modulates erythropoiesis through regulation of adult hepatic erythropoietin synthesis. Nat Med 2006;12:793-800. (Pubitemid 44050069)
18. Duda DG, Cohen KS, Scadden DT, Jain RK. A protocol for phenotypic detection and enumeration of circulating endothelial cells and circulating progenitor cells in human blood. Nat Protoc 2007;2:805-10. (Pubitemid 46745577)
19. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM. Reporting recommendations for tumor marker prognostic studies (REMARK). J Natl Cancer Inst 2005;97:1180-4. (Pubitemid 41258223)
20. Genovese T, Mazzon E, Crisafulli C, Di Paola R, Muia C, Bramanti P, et al. False discovery control with p-value weighting. Biometrika 2006:509-24.
21. Brown MB, Benedetti JK. Sampling behavior of tests for correlation in two-way contingency tables. J Am Stat Assoc 1977;72:309-15.
22. Naugler WE, Karin M. The wolf in sheep's clothing: the role of interleukin-6 in immunity, inflammation and cancer. Trends Mol Med 2008;14:109-19.
23. Duda DG, Cohen KS, Ancukiewicz M, di Tomaso E, Zhu AX, Penson RT, et al. A comparative study of circulating endothelial cell and circulating progenitor cell kinetics in four multidisciplinary phase 2 studies of antiangiogenic agents. Abstract 3544. ASCO Annual Meeting 2008.
24. Kumar R, Crouthamel MC, Rominger DH, Gontarek RR, Tummino PJ, Levin RA, et al. Myelosuppression and kinase selectivity of multikinase angiogenesis inhibitors. Br J Cancer 2009;101:1717-23.
25. Norden-Zfoni A, Desai J, Manola J, Beaudry P, Force J, Maki R, et al. Blood-based biomarkers of SU11248 activity and clinical outcome in patients with metastatic imatinib-resistant gastrointestinal stromal tumor. Clin Cancer Res 2007;13:2643-50. (Pubitemid 46788031)
26. Ko JS, Rayman P, Ireland J, Swaidani S, Li G, Bunting KD, et al. Direct and differential suppression of myeloid-derived suppressor cell subsets by sunitinib is compartmentally constrained. Cancer Res 2010;70:3526-36.
27. Llovet JM, Di Bisceglie AM, Bruix J, Kramer BS, Lencioni R, Zhu AX, et al. Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst 2008;100:698-711.
28. Finke JH, Rini B, Ireland J, Rayman P, Richmond A, Golshayan A, et al. Sunitinib reverses type-1 immune suppression and decreases T-regulatory cells in renal cell carcinoma patients. Clin Cancer Res 2008;14:6674-82.
29. Ko JS, Zea AH, Rini BI, Ireland JL, Elson P, Cohen P, et al. Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients. Clin Cancer Res 2009;15:2148-57.
30. Zhang W, Zhu XD, Sun HC, Xiong YQ, Zhuang PY, Xu HX, et al. Depletion of tumor-associated macrophages enhances the effect of sorafenib in metastatic liver cancer models by antimetastatic and antiangiogenic effects. Clin Cancer Res 2010;16:3420-30.
31. Jain RK, Duda DG, Willett CG, Sahani DV, Zhu AX, Loeffler JS, et al. Biomarkers of response and resistance to antiangiogenic therapy. Nat Rev Clin Oncol 2009;6:327-38.
32. Wartiovaara U, Salven P, Mikkola H, Lassila R, Kaukonen J, Joukov V, et al. Peripheral blood platelets express VEGF-C and VEGF which are released during platelet activation. Thromb Haemost 1998;80:171-5. (Pubitemid 28353517)
33. Carmeliet P. Angiogenesis in life, disease and medicine. Nature 2005;438:932-6. (Pubitemid 43093958)
34. Miksad RA, Lai KC, Stein MC, Healy ME, Rojas R, Krajewski KM, et al. Imbalance and gait disturbance from tyrosine kinase inhibition in hepatocellular cancer. J Gastrointest Cancer 2009;40:119-22.
35. Rini BI, Schiller JH, Fruehauf JP, Cohen EE, Tarazi JC, Rosbrook B, et al. Association of diastolic blood pressure (dBP) >90 mmHg with overall survival in patients treated with axitinib (AG-013736). J Clin Oncol 2008;26suppl: abstr 3543.